The Joker Arrives Today in FunPlus’ State of Survival
25.11.2021 22:20:00 EET | Business Wire | Press release
FunPlus, a leading mobile game developer and publisher, and its KingsGroup studio today welcome iconic DC Super-Villain, The Joker, as a new playable hero in State of Survival, the free-to-play strategy game available on both iOS and Android. Licensed by Warner Bros. Interactive Entertainment on behalf of DC, all players who complete the thrilling story campaign will have a limited window to permanently unlock The Joker for their roster.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211125006179/en/
THE JOKER ARRIVES TODAY IN FUNPLUS’ STATE OF SURVIVAL. DC Collaboration Brings Iconic Super-Villain to the Massively Popular Strategy Game (Graphic: Business Wire)
As one of the most well-known Super-Villains in pop culture, The Joker makes his State of Survival debut providing gamers and fans of the character an eventful campaign that combines zombies with his infamous maniacal behavior, offering a strategy experience like no other.
“FunPlus is proud of the success of State of Survival and its appeal to other brands in the entertainment space. As we wrap up our crossover with AMC’s The Walking Dead, we’re thrilled to be able to align with DC to incorporate The Joker, one of the most popular characters in entertainment,” said Chris Petrovic, Chief Business Officer of FunPlus. “We are excited to share this new campaign and encourage fans of The Joker to jump into State of Survival today!”
To see The Joker in action and for a glimpse into the storyline, check out the teaser trailer here .
For more information on DC, visit dccomics.com. For more information on FunPlus, visit http://www.funplus.com. For more information on State of Survival, visit https://funplus.com/games/state-of-survival/.
Find a link to assets HERE
About FunPlus
Founded in 2010, FunPlus is a world-class, independent game developer and publisher headquartered in Switzerland and with operations in China, Japan, Singapore, Spain, Sweden, Russia, and the United States.
As an organization that fosters the best creative and diverse talent in the world, and employs nearly 2,000 people, the company has developed and published games that have ranked in the #1 spot in nearly 70 countries, including State of Survival, King of Avalon and Guns of Glory.
FunPlus studios include KingsGroup, Puzala, Seven Games and Imagendary Studios, each with a focus on developing a unique brand of innovative games for global audiences.
FunPlus is the founder of FPX（FunPlus Phoenix), one of the world's most successful esports organizations, and the 2019 League of Legends World Champions.
About Warner Bros. Interactive Entertainment
Warner Bros. Interactive Entertainment is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information can be found at www.wbgames.com.
About DC
DC is one of the largest English-language publishers of comics and graphic novels in the world and home to some of the most iconic and recognizable characters ever created. As a creative unit of WarnerMedia, DC is charged with strategically integrating its stories and characters across film, television, consumer products, home entertainment, interactive games, and the DC UNIVERSE INFINITE digital subscription service and community engagement portal. For more information visitdccomics.com and dcuniverseinfinite.com.
™ & © DC Comics. ™ & © Warner Bros. Entertainment Inc. (s21)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006179/en/
Contact information
BHI for FunPlus
Jamie King
jamie_king@bhimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom